Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034904 | 0.85 | SMN1; SMN2 (0.42) | TLR8 | |
| SCHEMBL6035551 | 0.82 | CYP4F2 (0.41) | NOTUMDGAT1TRPA1 | |
| SCHEMBL6036260 | 0.82 | ALDH1A1 (0.35) | TLR8DGAT1FFAR4PPARDPPARA | |
| SCHEMBL6036189 | 0.81 | TLR8 (0.44) | NOTUMTLR8TRPA1SCN9AFFAR4 | |
| SCHEMBL6035734 | 0.79 | PPARD (0.46) | PPARDPPARA | |
| SCHEMBL6034564 | 0.78 | PPARD (0.46) | PPARDPPARA | |
| SCHEMBL6034578 | 0.78 | TLR8 (0.44) | NOTUMTLR8TRPA1SCN9ASRC | |
| SCHEMBL6035564 | 0.78 | PLA2G4B (0.42) | DGAT1PPARDPPARA | |
| SCHEMBL6034531 | 0.78 | SMN1; SMN2 (0.43) | SCN9A | |
| SCHEMBL16634906 | 0.77 | TRPA1 (0.49) | NOTUMTRPA1SCN9ASRCBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | NOTUM 1167/4885TLR8 4191/4885DGAT1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.